
| Tri-Luma® on TV |
| Learn more about Tri-Luma, the first triple-action cream for the short-term treatment of moderate to severe melasma.
|
|
Expert Advice
|
Learn more about managing melasma with Dr. Janet Allenby. Dr. Allenby is a board certified dermatologist and a leading expert in cosmetic dermatology.
In these videos, Dr. Allenby addresses the following: |
See how melasma occurs and how Tri-Luma® Cream helps
reduce the discoloration.
|
Janet Allenby a board certified dermatologist provides a full range of services, including the latest techniques in cosmetic dermatology, laser surgery and diagnosis & treatment of skin conditions.
After 10 years of practice in dermatology, Dr. Allenby has become a leading expert in the field of cosmetic dermatology. She is a well-known lecturer who speaks to dermatologists and pharmaceutical companies both nationally and internationally.
|
 |
Tri-Luma® Cream is contraindicated in individuals with a hypersensitivity, allergy or intolerance to fluocinolone acetonide, hydroquinone or tretinoin. In clinical trials, the most frequently reported side effects were erythema, desquamation, burning, dryness and pruritus.
Mild to moderate redness, peeling, burning, dryness or itching may be experienced. This product contains sulfites that may cause severe allergic reactions including anaphylactic symptoms and life-threatening asthma attacks. Exposure to sunlight, sunlamps or UV light and extreme heat, wind or cold should be avoided. Use of sunscreen with appropriate SPF of 30 or higher is required. Wear protective clothing and change to nonhormonal forms of birth control, if hormonal methods are used.
Tri-Luma® Cream contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, whose occurrence should prompt discontinuation of therapy. Tri-Luma® Cream contains the corticosteroid fluocinolone acetonide. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment.